Kornimate/medical-research-clean huggingface dataset:
the effect of inhibitory control processes induced by rectal distension on impulse control measured by stroop task performance and intertemporal discounting.

Conditions: Healthy Subjects

Summary: the aim of this study will be to investigate the effect of rectal distension, controlled by electronic barostat, on cognitive control ability in healthy subjects. we will use the stroop task and an intertemporal choice task as standard instruments. like bladder control and rectal control, both stroop task performance and intertemporal choices - though very different tasks at the surface - are dependent on the conflict monitoring function of the anterior cingulate cortex. the stroop task requires the naming of the print color of a series of visually presented color words, and reaction time and error rates are typically used as performance indicators. when word color and word meaning do not match, performance of the task (color naming) requires the inhibition of a (near) automatic response (word reading). the intertemporal choice task consists of a series of choices between a sooner smaller monetary reward and a larger but later reward. the choices are constructed such that they allow the estimation of a discount parameter, which is an index for the level of impulsiveness manifested by the participant at the time the choices are made. the hypothesis is that the inhibition induced by the urge generated during rectal distension will improve cognitive inhibitory performance, as has previously been shown for bladder filling.


Eligibility criteria:
inclusion criteria: * healthy male and non-pregnant, non-breastfeeding female participants, aged 18-60 years old at the time of consent. exclusion criteria: * use of medications within 48 h of dose initiation; structural or metabolic diseases that affect the gastrointestinal system and functional gastrointestinal disorders; previous abdominal surgery other than appendectomy, cholecystectomy, hysterectomy, or hernia repair; known illnesses such as diabetes, cardiovascular or lung disease; current psychiatric disorders (anxiety, depression, substance use); use of agents that influence bowel habit, i.e. anticholinergics (not including antihistamines with anticholinergic properties), spasmolytics and prokinetics in the 7 days before the study.
"peripheral blood dipeptidylpeptidase iv (cd26) positive leukemic stem cells in chronic myeloid leukemia as a diagnostic marker"

Conditions: Chronic Myeloid Leukemia, Chronic Phase

Summary: chronic myeloid leukemia (cml) is a stem cell (sc) neoplasm which originates from an incomplete process of differentiation of the hematopoietic stem cells (hscs) to the adult cells which lead to accumulation of their immature form into the bm and the peripheral blood. it is characterized by the reciprocal translocation. the resulting oncoprotein, bcr/abl1, is considered essential for the initiation and manifestation of the disease . in cml, leukemic stem cell (lsc) supposedly resides within the cd45+/ cd34+/cd38-/lin- fraction of the leukemic clone (3). however, normal hematopoietic sc also exhibit this phenotype so that additional markers are required to discriminate cml lsc from normal sc. cd34+/cd38-/lin- cml lsc specifically co-express dipeptidylpeptidase iv(dppiv=cd26). this enzyme disrupts lsc-niche interactions by degrading stroma derived factor-1 (sdf-1). moreover, cd26 is a robust biomarker for the quantification and isolation of cml lsc (4). it was reported that cd26+ lscs were significantly correlated with bcr-abl1 transcript level at diagnosis and after three months of treatment with tyrosine kinase inhibitor (tki) .


Eligibility criteria:
inclusion criteria: * : all suspected patients for cml diagnosis aged more than 18 years who presented with high white blood cells(wbcs) count , marked shift to left in peripheral blood with or without splenomegaly . exclusion criteria: * patients on treatment or presence of blasts in peripheral blood sample.
dopamine agonists withdrawal study of invasive prolactinomas involving the cavernous sinus

Conditions: Invasive Prolactinomas Involving the Cavernous Sinus

Summary: the purpose of this study is to observe whether dopamine agonists can be safely withdrawn after the tumor volume and prolactin level of invasive prolactinomas involving the cavernous sinus have been effectively controlled through pharmacological treatment.

for giant or large invasive prolactinomas involving the cavernous sinus, whether the drug can be safely withdrawn after the tumor volume and prolactin(prl) level have been effectively controlled through pharmacological treatment still remains unknown. the study objects are patients with invasive prolactinomas involving the cavernous sinus, which were invaded the cavernous sinus to an extent corresponding to grade iii or iv, according to the classification scheme of knosp and colleagues, who had undergone pharmacological treatment including bromocriptine or cabergoline. observation will be started after drug withdrawal criteria are reached (prl remains normal level for no less than two years; tumor volume has shrank more than 50%, and the distance is more than 5mm between tumor and optical nerve),the patients are randomized to withdrawal group or continue treatment group.observational items include changes of prl level, tumor volume as well as vision acuity and visual fields. if elevated prl or tumor relapse is observed, pharmacological treatment will be restarted.

Eligibility criteria:
inclusion criteria: 1. aged between 15 and 70 years old, either sex; 2. karnofsky performance status ≥ 70; 3. patients who were suffered invasive prolactinomas involving the cavernous sinus , referring to ①serum prolactin level\>200ng/ml, or \>4000miu/l;②enhanced magnetic resonance images confirm tumor invasion into cavernous sinus, i.e. knosp grade ⅲ or ⅳ, and were treated by dopamine agonists treatment; 4. prl remains normal level for no less than two years; 5. tumor volume has shrank more than 50%, and the distance is more than 5mm between tumor and optical nerve; 6. the patient has signed the informed consent. exclusion criteria: 1. patients concomitantly taking the psychotropic drugs or other drugs causing elevated prl ; 2. patients with parkinson disease and is taking dopaminergic agents; 3. patients with prolactinoma who received gamma knife treatment; 4. patients who use any dopamine receptor agonists other than bromocriptine and cabergoline; 5. patients taking the other prolactinomas simultaneously; 6. pregnant or lactating women, or women preparing pregnant; 7. patients with poor compliance, who cannot implement the program strictly.

Keywords: prolactinoma dopamine agonist withdrawal cavernous sinus
impact of speac® system data on therapeutic decisions related to convulsive seizure patients with a new diagnosis

Conditions: Epilepsy

Summary: this is an open label, randomized, prospective study of the impact on healthcare utilization of a surface electromyography (semg) based seizure monitoring and alerting system for veterans with a history of motor seizures (epileptic, non-epileptic or unknown) with upper extremity motor involvement, presenting with questionable spell characterization, taking place in the home setting.


Eligibility criteria:
inclusion criteria: 1. subject is a veteran with a reported history of motor seizures (epileptic, non-epileptic or unknown) with upper extremity motor involvement, presenting with questionable spell characterization. 2. subjects has failed fewer than 3 anti-epileptic drugs (single or combination). 3. male or female between the ages 22 to 99. 4. if female and of childbearing potential, subject must agree to not become pregnant during the trial. 5. can understand and sign written informed consent or will have a legally authorized representative (lar) who can do so, prior to the performance of any study assessments. 6. subject or primary caregiver must be competent to follow all study procedures. 7. subject must be willing to use the seizure monitoring and alerting system for a prolonged period of time (up to 120 days), for a minimum of 30 hours/ week. exclusion criteria: 1. the subject cannot be pregnant, or nursing. 2. the subject cannot be sensitive or allergic to adhesives or tapes. 3. the subject may not be enrolled in another clinical trial. 4. the subject is homeless or in a home without a power supply.
pharmacokinetics, safety, tolerability and efficacy of intravenous doses of zgn-433 in obese female volunteers

Conditions: Obesity

Summary: the purpose of this study is to assess whether multiple doses of zgn-433 are safe and effective.

this protocol is designed to test the safety and efficacy of a drug called beloranib (zgn-433). it is to be tested for its ability to reduce weight in obese female subjects who are of non-childbearing potential. the study will provide information on how much zgn-433 gets into the blood, how long it stays in the body, and how it affects other biological markers.

Eligibility criteria:
inclusion criteria: * obese but otherwise healthy females * non-childbearing potential (surgically sterile, post-menopausal, or receiving implanted or injectable contraceptive for at least 3 months) * bmi ≥ 30 and ≤ 50 kg/m2 * stable body weight during the past month exclusion criteria: * use of weight loss agents in the past month * history of eating disorder * history of gastric bypass surgery * current smokers

Keywords: obese obesity overweight
epinephrine and cortisol in depression

Conditions: Depression

Summary: this study investigates the effects of two hormones called epinephrine and cortisol on how the brain processes emotional material using functional mri to measure brain activity. the study hopes to learn how epinephrine and cortisol affect the brain differently in depressed and non-depressed individuals.


Eligibility criteria:
inclusion criteria: * weight of less than 280 pounds * ham-d score of greater than 7 for depression participants exclusion criteria: * psychotropic medications * recent surgery * endocrine disorders * liver disease * kidney disease * thyroid disorder * history of malaria * tuberculosis * osteoporosis * glaucoma or cataracts * chronic expressed infections (herpes, hiv, etc) * history of congestive heart failure * history of recurring seizures * stomach ulcers * comorbid psychosis * current use of illicit drugs * diabetes * any cardiovascular disease (angina, hypovolemia, coronary artery disease, low/high blood pressure, etc) * any pulmonary disease * any cerebrovascular disease * sulfate hypersensitivity * glaucoma * infection * pregnancy * parkinson's disease * panic disorder * over 280 pounds in weight * in-dwelling ferrous metals * left handed * abnormal hearing * claustrophobic * head injury with loss of consciousness * active suicidal ideation
vitamin d and serum calcium level insufficiency and early dental implant failure

Conditions: Vitamin D Deficiency; Dental Implant Failure Nos

Summary: in this study there is a trial to investigate whether there is a correlation between early implant failure and low serum levels of vitamin d.

osseointegration is a complex phenomenon and depends on many factors; some are related to the implant (material, macroscopic design, and implant surface), others to the surgical-prosthetic protocol (surgical technique, loading conditions, and time), and others to the patient (quantity/quality of bone at the receiving site and the host response) all these observations would suggest the existence of specific patient-related risk factors such as vitamin d deficiency in the blood, could play an important role in the occurrence of early dental implant failures (edifs), but unfortunately are neglected by the dental literature. in this study there is a trial to investigate whether there is a correlation between early implant failure and low serum levels of vitamin d. therefore we are including patients with early implant failure during the year 2020 using the same implant (material, macroscopic design, and implant surface), surgical-prosthetic protocol (surgical technique, loading conditions, and time) the study will be performed into 15 male and 15 female participants that had dental implant placement in the last 3 months. an informed consent will be signed with the patient with full detail on the study. the situation of the implant will be categorized into either successful or failed dental implant. medical history and lifestyle information will be obtained by questionnaire. levels of serum vitamin d will be collected from participants statistical analysis will correlate between vitamin d and early implant failure.

Eligibility criteria:
inclusion criteria: * missing single tooth * systemically free * average body mass index exclusion criteria: * systemic conditions * bad oral hygiene
applying proton pump inhibitor to prevent and treat acute fluctuating hearing loss in patients with slc26a4 mutation

Conditions: Hearing Loss

Summary: disequilibrium between acid and base in the inner ear was suggested to be an important factor leading to hearing impairment associated with slc26a4 mutations. for acid-base homeostasis in the inner ear, gastric-type proton pumps might demonstrate antagonistic effects to pendrin, the protein encoded by slc26a4. to investigate whether proton pump inhibitors might prevent or treat acute fluctuating hearing loss related to slc26a4 mutations, we launch the current double-blind randomized clinical trial.

hereditary hearing loss is the most common inherited sensory defect, affecting about 1 per 1000 children. with the advances in molecular genetics, the nature of hereditary hearing loss has started to be unraveled. a plethora of deafness genes were discovered in the past years, and among them certain genetic mutations were noted to be extraordinarily popular in the hearing-impaired population. for example, mutations in the slc26a4 gene have been documented with high prevalence in a variety of ethnic backgrounds, including caucasians, japanese and han chinese. the two specific clinical features of patients with slc26a4 mutations are inner ear malformations and fluctuating hearing loss. for decades, the latter has constituted a treatment difficulty for pediatric otologists, because traditional regimens, such as steroid or intracranial-pressure-lowering-medication, usually could not achieve satisfactory and predictable outcomes. nevertheless, as basic researches in recent years began to shed light on the pathogenesis of hearing loss from slc26a4 mutations, novel strategies could be developed based on some of these crucial findings. for instance, disequilibrium between acid and base in the inner ear was reported to be an important factor leading to deafness in slc26a4 knock-out mice. and for acid-base homeostasis in the inner ear, proton pumps were found to demonstrate antagonistic effects to pendrin, the protein encoded by slc26a4. consequently, regimens which can modulate the function of proton pumps, like proton pump inhibitors, might be a good choice to prevent or treat acute or chronic hearing loss related to slc26a4 mutations or degenerative dysfunction. corresponding to this postulation, clinically we experienced significant recovery of hearing loss in several patients with slc26a4 mutations who suffered from acute fluctuating hearing loss which was refractory to traditional treatment. in some cases, acute hearing loss recurred after the medication was discontinued. therefore, we launch the current clinical trial to investigate the efficacy of proton pump inhibitor in preventing and treating acute hearing loss in patients with slc26a4 mutations.

Eligibility criteria:
inclusion criteria: * patients with homozygous or heterozygous slc26a4 mutations * patients with acute hearing loss exclusion criteria: * patients who do not fulfill both of the above criteria

Keywords: acute hearing loss in patients with slc26a4 mutations
fecal microbiota transplantation for constipation

Conditions: Gut Microbiota; Constipation

Summary: difficult defecation is a common symptom involving with patients'life quality. the stool pattern of these patients might be related to the contribution of gut microbiota. this pilot study proposed hypothesis that stool pattern could be used as a simple index to screen the potential candidates of fecal microbiota transplantation in patients with difficult defecation.

difficult defecation is a common symptom involving with patients'life quality. the stool pattern of these patients might be related to the contribution of gut microbiota. this pilot study proposed hypothesis that stool pattern could be used as a simple index to screen the potential candidates of fecal microbiota transplantation in patients with difficult defecation. patients underwent single fmt in this study were divided into hard-stool group and loose-stool group. all patients were assessed before fmt and during 12-week follow-up after fmt.

Eligibility criteria:
inclusion criteria: 1. age between 14-80 years old; 2. difficult defecation with more than six months (a. straining during defecation; b. sensation of incomplete evacuation; c. sensation of anorectal blockage; d. manual maneuvers to facilitate defecation). exclusion criteria: 1. difficult defecation due to secondary factors (e.g. drugs, pelvic surgery, psychiatric disorders); 2. with history of gastrointestinal diseases such as cancer, inflammatory bowel diseases (ibd); 3. pregnant or breast-feeding women; 4. infection with pathogenic bacteria. enrolled patients were divided into hard-stool group and loose-stool group according to their stool patterns. all patients were followed up for 12 weeks.

Keywords: difficult defecation fecal microbiota transplantation stool pattern
the study is enrolling kids from 8 to 17 years old. the breathsmart device attaches to the inhaler to measure adherence.

Conditions: Asthma

Summary: non-adherence to controller medication is a common problem in children with asthma, resulting in overuse of reliever medication, increased asthma symptoms, more frequent asthma attacks, and increased emergency room visits and hospital admissions. additionally, current absence of a gold standard to measure adherence forces clinicians and researchers to rely on patient-self report, which is notoriously inaccurate, to support clinical decision making. many young patients suffer from both intentional and non-intentional non-adherence, thus an appropriate intervention must address both types. current studies using electronic monitoring devices (emds) primarily focus on non-intentional non-adherence through reminder systems and thus are limited in their ability to engage patients for long-term behavior change. this trial addresses an important knowledge gap by evaluating whether emds with a combination of reminder system and patient education can prove to be effective in increasing adherence rates and can be used in clinical practice to achieve better asthma control and outcomes through improved patient and clinician engagement.

this is a prospective, randomized, controlled study of children with persistent asthma who are managed on daily inhaled corticosteroids (ics). 75 children will be randomized 2:1 into one of two arms: * 50 children will be randomized to breathesmart, comprised of: * breathesmart mobile application that tracks medication usage and sends real time reminders * herotracker sensor that counts dosage and monitors real-time medication adherence * coheroconnect provider portal that allows the investigator to monitor real-time adherence and to provide targeted outreach to children with low adherence (intervention arm) * 25 children will be randomized to "standard of care"(control arm). these patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.

Eligibility criteria:
inclusion criteria: * age 8 to 17 * diagnosis of persistent asthma * prescribed an inhaled corticosteroid (ics) for at least one month prior to enrollment * use of a pressurized metered dose inhaler (pmdi) compatible with the cohero mhealth herotracker (see appendix) * parent/child possess a compatible smartphone (ios 8.0 or higher) * english or spanish speaking exclusion criteria: * presence of another chronic lung disease or condition such as cystic fibrosis, interstitial lung disease, chronic lung disease of prematurity, recurrent aspiration, or presence of tracheostomy * presence of other chronic medical condition such as congenital heart disease or immunodeficiency * presence of other comorbidities that, in the opinion of the investigator, will interfere with collection of study procedures, or limits life expectancy to \< 1 year * currently pregnant or planning to become pregnant during the trial period

Keywords: asthma
the effect of olive leaf extract on blood pressure in overweight prehypertensives

Conditions: Hypertension

Summary: cardiovascular disease (cvd) is the leading cause of death in new zealand (40% of all deaths). 37% of new zealanders suffer from high blood pressure (world health organisation 2008 figures), a well established modifiable risk factor for cvd. above 115/75 mmhg, cvd risk doubles for each increment of 20/10 mmhg that blood pressure is raised. an increase in bmi and waist circumference has been associated with an increase in blood pressure. the leaves of the olive plant are rich in plant compounds known as polyphenols. this particular group of polyphenols are known secoiridoids, which are also present in olive oil and olives though at lower concentrations, are only found in this family of plants. diets high in polyphenols have been found to reduce the risk of chronic diseases. studies have shown that consumption of phenolic-rich olive leaf extract (ole) can significantly reduce blood pressure in individuals suffering from high blood pressure (hypertension), with the magnitude of effect being comparable to a commonly used antihypertensive drug. in such trials ole also resulted in an improved blood lipid (a reduction in total and ldl cholesterol and triacylglycerides) which also reduces cvd risk. one study testing the effect of ole on individuals with mild or prehypertension (i.e. those with systolic blood pressure in the range 121-139 mmhg and diastolic blood pressure in the range 81-89 mmhg but not taking antihypertensive medication) also found these same improvements. ole has been indicated to have the potential to improve other cardiovascular risk markers such as vascular function, inflammation, platelet aggregation, oxidation of ldl and glucose tolerance however much of this evidence is derived from animal, in vitro and ex vivo studies and so well designed and controlled human studies are required to verify that these findings are applicable to humans. therefore ole supplementation may be a useful dietary strategy for reducing cvd risk in a cohort of overweight prehypertensive individuals. the aim of the study is to determine the effect of ole intake on blood pressure and other cvd risk markers in overweight subjects with mild hypertension and to link any study outcomes with the presence of ole phenolics in urine


Eligibility criteria:
inclusion criteria: men 18-65 years; non-smokers; prepared to consume olive leaf extract liquid systolic blood pressure 121-139 mmhg and diastolic blood pressure 81-89 mmhg body mass index (bmi) between 25-30 kg/m2 or waist \>102 cm exclusion criteria: smokers using blood pressure, lipid lowering, thyroid disorder, blood clotting medication using supplements or functional foods that will affect lipid concentrations (e.g. sterol enriched spreads) chronic disease e.g. chd, diabetes, cancer, digestive disorders individuals who are unwilling to refrain from consuming olive containing products for the duration of the study